Margaret Kaczor Andrew Highlights Abbott’s New Obesity Drug in Investor’s Business Daily

William Blair research analyst Margaret Kaczor Andrew was quoted in Investor’s Business Daily on the implications of Abbott receiving FDA approval for two drugs aimed at obesity care—Lingo and Libre Rio.

“The broad approval—as well as the (over-the-counter) indication, which eliminates the need for a prescription—increases the (total addressable market) by many multiples," Kaczor Andrew’s note to investors that was cited by the publication said.